Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
Fabry disease experts discuss early diagnosis, organ monitoring, long-term individualized care and future directions.
Watch three experts discuss the clinical management of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
Finerenone (a selective nonsteroidal mineralocorticoid receptor antagonist) and the SGLT2 inhibitor empagliflozin may reduce both kidney and cardiovascular risks in people with chronic kidney disease and type 2 diabetes. It is unknown whether dual therapy with finerenone and empagliflozin is superior ...
There is a high unmet need for new treatments to preserve kidney function and delay kidney disease progression in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). In this touchENDOCRINOLOGY interview, Prof. Jennifer Green (Duke University School ...
Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D
SUSTAIN 6 and PIONEER 6 investigated the effects of semaglutide versus placebo on major adverse cardiovascular events (MACE). The current post hoc analysis investigated the association between baseline kidney function and risk of MACE, and the effect of semaglutide on risk of ...
Chronic kidney disease (CKD) is a common diabetes-related complication among type 2 diabetes (T2DM) patients, with a high prevelance within primary care settings. In this touchENDOCRINOLOGY interview, we speak with Dr Sara (Mandy) Reece (Philadelphia College of Osteopathic Medicine (PCOM), ...
The current treatment options for chronic kidney disease in patients with type 2 diabetes is discussed by Professor Hiddo Heerspink (University Medical Center Groningen, Groningen, Netherlands). Also discussed is the mechanism of tirzepatide, a novel once-weekly medication, which has shown to ...
A pre-specific exploratory analysis of SURPASS-4 evaluated the progression to pre-specified kidney endpoints between tirzepatide and titrated daily insulin glargine in chronic kidney disease. Professor Hiddo Heerspink (University Medical Center Groningen, Groningen, Netherlands) discusses the outcome of the analysis and ...
The combined use of finerenone and glucagon-like peptide-1 receptor agonist (GLP-1RA) for chronic kidney disease (CKD) and type 2 diabetes (T2D) was studied in the FIDELITY analysis, and is discussed by Professor Peter Rossing (Steno Diabetes Center, Copenhagen, Denmark). ...
Chronic kidney disease (CKD) represents one of the greatest future public health challenges due, among other consequences, to its elevated burden on economic and human resources within healthcare systems.1Â Moreover, the rapid growth of type 2 diabetes mellitus (T2DM) results ...
Hyperinsulinaemic Hypoglycaemia (HH) is a very rare disease with an estimated incidence of 1/50,000,1 and includes a clinical, histological and genetic heterogeneous group of disorders characterised by hypoglycaemia, hyperinsulinism or, more specifically, increased C-peptide level and inappropriate low blood levels of ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.